Coronavirus USA summary: news, cases, deaths – 29 August

Spread the love

Sanofi more confident about its coronavirus vaccines

(Reuters) Sanofi’s confidence in its coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to start clinical trials, its chief executive told Reuters.

The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the Covid-19 pandemic, which has claimed more than 831,000 lives and sparked economic chaos.

One candidate, to be manufactured on the back of an existing platform that develops vaccines to treat flu, will use an adjuvant made by Britain’s GlaxoSmithKline (GSK) to boost its efficacy.

The other, being developed with US company Translate Bio , relies on a different technology known as mRNA.

The early data is saying that we’re on the right track and that we have a vaccine,” Paul Hudson said in an interview on Friday, referring to the vaccine being developed with GSK.

That vaccine is set to start clinical trials next month.

Around 30 experimental coronavirus shots are already in human trials. But Hudson said in June the probability of Sanofi obtaining a vaccine with an efficacy of more than 70% was higher than for rivals, in part due to its experience in vaccines.

Comments are closed, but trackbacks and pingbacks are open.